110 related articles for article (PubMed ID: 24445718)
1. ACP Journal Club. Review: in type 2 diabetes, dipeptidyl peptidase-4 inhibitors do not increase pancreatitis.
Morey-Vargas OL; Montori VM
Ann Intern Med; 2014 Jan; 160(2):JC8-9. PubMed ID: 24445718
[No Abstract] [Full Text] [Related]
2. ACP Journal Club. Incretin use was not associated with increased risk for acute pancreatitis.
Schectman J
Ann Intern Med; 2015 Jun; 162(12):JC12. PubMed ID: 26075777
[No Abstract] [Full Text] [Related]
3. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
Xu L; Spinas GA; Niessen M
Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
[No Abstract] [Full Text] [Related]
4. GLP-1-based therapies: the dilemma of uncertainty.
Spranger J; Gundert-Remy U; Stammschulte T
Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985
[No Abstract] [Full Text] [Related]
5. Potential linkage between dipeptidyl peptidase-4 inhibitor use and the risk of pancreatitis/pancreatic cancer.
Shirakawa J; Terauchi Y
J Diabetes Investig; 2020 Jul; 11(4):789-791. PubMed ID: 31774618
[No Abstract] [Full Text] [Related]
6. Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors.
Lee M; Sun J; Han M; Cho Y; Lee JY; Nam CM; Kang ES
Diabetes Care; 2019 Nov; 42(11):2057-2064. PubMed ID: 31431452
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Mannucci E
Diabetes Obes Metab; 2014 Jan; 16(1):48-56. PubMed ID: 23837679
[TBL] [Abstract][Full Text] [Related]
8. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
de Heer J; Göke B
Expert Opin Drug Saf; 2014 Nov; 13(11):1469-81. PubMed ID: 25270593
[TBL] [Abstract][Full Text] [Related]
9. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
Nauck MA; Meier JJ; Schmidt WE
Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
[No Abstract] [Full Text] [Related]
10. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
Raz I; Bhatt DL; Hirshberg B; Mosenzon O; Scirica BM; Umez-Eronini A; Im K; Stahre C; Buskila A; Iqbal N; Greenberger N; Lerch MM
Diabetes Care; 2014 Sep; 37(9):2435-41. PubMed ID: 24914244
[TBL] [Abstract][Full Text] [Related]
11. The safety of incretin based drug treatments for type 2 diabetes.
Bolen SD; Maruthur NM
BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
[No Abstract] [Full Text] [Related]
12. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
Olansky L
Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
[No Abstract] [Full Text] [Related]
13. The safety of incretin based drugs.
Montori VM
BMJ; 2014 Apr; 348():g2779. PubMed ID: 24764568
[No Abstract] [Full Text] [Related]
14. Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
Smits MM; Muskiet MH; Tonneijck L; van Raalte DH
Diabetes Care; 2015 Jul; 38(7):e106-7. PubMed ID: 26106231
[No Abstract] [Full Text] [Related]
15. Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
Diabetes Care; 2015 Jul; 38(7):e108-9. PubMed ID: 26106232
[No Abstract] [Full Text] [Related]
16. Preying on the pancreas? Scientists debate whether newer diabetes medications do harm.
Berg EG
Diabetes Forecast; 2013 Oct; 66(10):26, 28, 30-1. PubMed ID: 24224353
[No Abstract] [Full Text] [Related]
17. Association Between Pancreatic Cancer and Dipeptidyl Peptidase-4 Inhibitors Use in a Case-Control Study.
Lai SW; Lin CL; Liao KF
Mayo Clin Proc; 2018 Dec; 93(12):1874-1876. PubMed ID: 30522598
[No Abstract] [Full Text] [Related]
18. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.
Roshanov PS; Dennis BB
Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128
[TBL] [Abstract][Full Text] [Related]
19. Acute pancreatitis with dipeptidyl peptidase-4 (DPP4) inhibitor or fulminant type 1 diabetes?
Amouyal C; Levy P; Andreelli F; Hartemann A
Diabetes Metab; 2018 Feb; 44(1):95-96. PubMed ID: 28483292
[No Abstract] [Full Text] [Related]
20. Vildagliptin-induced acute pancreatitis without enzyme elevation.
Mungan Z; Attila T; Ünal Kabaoğlu Z; Vural M
Turk J Gastroenterol; 2017 Nov; 28(6):514-517. PubMed ID: 29086719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
